Literature DB >> 27575943

Detection and Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Thyroid Cancer.

Jian Yu Xu1, Beverly Handy1, Christina L Michaelis1, Steven G Waguespack1, Mimi I Hu1, Naifa Busaidy1, Camilo Jimenez1, Maria E Cabanillas1, Herbert A Fritsche1, Gilbert J Cote1, Steven I Sherman1.   

Abstract

CONTEXT: Individual patient prognostication for advanced thyroid cancer (TC) is challenging. Circulating tumor cells (CTCs) have been shown to be a valuable prognostic marker for other solid cancers.
OBJECTIVE: We hypothesized that CTCs are present in the blood of patients with advanced TC and their number can predict overall survival (OS).
SETTING: This is a prospective study at a tertiary cancer hospital. Patients, Interventions, and Main Outcome Measures: Initial studies were performed with TC cell lines to determine the feasibility of detection using the Veridex CellSearch. CTC enumeration was performed in blood samples from 18 patients with distantly metastatic medullary TC (metMTC), 14 with distantly metastatic differentiated TC (metDTC), and 10 controls with a history of TC but no evidence of disease. The prognostic value of CTC levels to predict OS in metMTC patients was assessed.
RESULTS: CellSearch detected cells from MTC and DTC but not anaplastic TC cell lines. Six metMTC patients but no metDTC or control patients had more than or equal to 5 CTCs detected by the CellSearch assay. Median survival in metMTC patients with more than or equal to 5 CTCs was 13 months vs 51.5 months for those with less than 5 CTCs (P = .0116). The hazard ratio for mortality of patients with more than or equal to 5 CTCs compared with those with less than 5 CTCs was 3.95 (1.20-13.0, P = .0245).
CONCLUSIONS: The presence of more than or equal to 5 CTCs in patients with metMTC is associated with worse OS. Larger cohorts are required to validate the prognostic value of CTC enumeration.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27575943      PMCID: PMC5095245          DOI: 10.1210/jc.2016-2567

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

1.  EpCAM overexpression in thyroid carcinomas: a histopathological study of 121 cases.

Authors:  Christian Ensinger; Roswitha Kremser; Rupert Prommegger; Gilbert Spizzo; Kurt W Schmid
Journal:  J Immunother       Date:  2006 Sep-Oct       Impact factor: 4.456

2.  Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.

Authors:  Massimo Cristofanilli; Daniel F Hayes; G Thomas Budd; Mathew J Ellis; Alison Stopeck; James M Reuben; Gerald V Doyle; Jeri Matera; W Jeffrey Allard; M Craig Miller; Herbert A Fritsche; Gabriel N Hortobagyi; Leon W M M Terstappen
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

3.  Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer.

Authors:  Matthew G Krebs; Robert Sloane; Lynsey Priest; Lee Lancashire; Jian-Mei Hou; Alastair Greystoke; Tim H Ward; Roberta Ferraldeschi; Andrew Hughes; Glen Clack; Malcolm Ranson; Caroline Dive; Fiona H Blackhall
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

4.  Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.

Authors:  W Jeffrey Allard; Jeri Matera; M Craig Miller; Madeline Repollet; Mark C Connelly; Chandra Rao; Arjan G J Tibbe; Jonathan W Uhr; Leon W M M Terstappen
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

5.  The influence of radioiodine therapy on the number of circulating epithelial cells (CEC) in patients with differentiated thyroid carcinoma - a pilot study.

Authors:  T Winkens; K Pachmann; M Freesmeyer
Journal:  Exp Clin Endocrinol Diabetes       Date:  2014-04-25       Impact factor: 2.949

6.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Authors:  Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes
Journal:  N Engl J Med       Date:  2004-08-19       Impact factor: 91.245

7.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.

Authors:  Steven J Cohen; Cornelis J A Punt; Nicholas Iannotti; Bruce H Saidman; Kert D Sabbath; Nashat Y Gabrail; Joel Picus; Michael Morse; Edith Mitchell; M Craig Miller; Gerald V Doyle; Henk Tissing; Leon W M M Terstappen; Neal J Meropol
Journal:  J Clin Oncol       Date:  2008-07-01       Impact factor: 44.544

8.  Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer.

Authors:  M Craig Miller; Gerald V Doyle; Leon W M M Terstappen
Journal:  J Oncol       Date:  2009-12-09       Impact factor: 4.375

9.  An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma.

Authors:  Helen C-H He; Lawrence Kashat; Ipshita Kak; Tada Kunavisarut; Raefe Gundelach; Dae Kim; Anthony K-C So; Christina MacMillan; Jeremy L Freeman; Ranju Ralhan; Paul G Walfish
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

10.  Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.

Authors:  Jeffrey B Smerage; William E Barlow; Gabriel N Hortobagyi; Eric P Winer; Brian Leyland-Jones; Gordan Srkalovic; Sheela Tejwani; Anne F Schott; Mark A O'Rourke; Danika L Lew; Gerald V Doyle; Julie R Gralow; Robert B Livingston; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2014-06-02       Impact factor: 50.717

View more
  10 in total

1.  Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.

Authors:  Gilbert J Cote; Caitlin Evers; Mimi I Hu; Elizabeth G Grubbs; Michelle D Williams; Tao Hai; Dzifa Y Duose; Michal R Houston; Jacquelin H Bui; Meenakshi Mehrotra; Steven G Waguespack; Naifa L Busaidy; Maria E Cabanillas; Mouhammed Amir Habra; Rajyalakshmi Luthra; Steven I Sherman
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

2.  Epithelial-to-mesenchymal transition of circulating tumor cells and CD133 expression on predicting prognosis of thyroid cancer patients.

Authors:  Deyu Li; Na Li; Ying Ding
Journal:  Mol Clin Oncol       Date:  2022-08-01

3.  CIRCULATING TUMOR CELLS IN MINIMALLY INVASIVE FOLLICULAR THYROID CARCINOMA AND BENIGN THYROID TUMORS WITH A FOLLICULAR PATTERN: PILOT EXPERIENCE.

Authors:  C I Badulescu; R J Marlowe; A Piciu; R Buiga; O Barbos; N I Bejinariu; G Chereches; E Barbus; E A Bonci; D Piciu
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Jan-Mar       Impact factor: 0.877

Review 4.  American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.

Authors:  David C Shonka; Alan Ho; Ashish V Chintakuntlawar; Jessica L Geiger; Jong C Park; Nagashree Seetharamu; Sina Jasim; Amr H Abdelhamid Ahmed; Keith C Bible; Marcia S Brose; Maria E Cabanillas; Kirsten Dabekaussen; Louise Davies; Dora Dias-Santagata; James A Fagin; William C Faquin; Ronald A Ghossein; Raj K Gopal; Akira Miyauchi; Yuri E Nikiforov; Matthew D Ringel; Bruce Robinson; Mabel M Ryder; Eric J Sherman; Peter M Sadow; Jennifer J Shin; Brendan C Stack; R Michael Tuttle; Lori J Wirth; Mark E Zafereo; Gregory W Randolph
Journal:  Head Neck       Date:  2022-03-11       Impact factor: 3.821

Review 5.  Next-generation sequencing in thyroid cancer.

Authors:  Yoon Jin Cha; Ja Seung Koo
Journal:  J Transl Med       Date:  2016-11-21       Impact factor: 5.531

Review 6.  Extracellular Vesicles from Thyroid Carcinoma: The New Frontier of Liquid Biopsy.

Authors:  Germana Rappa; Caterina Puglisi; Mark F Santos; Stefano Forte; Lorenzo Memeo; Aurelio Lorico
Journal:  Int J Mol Sci       Date:  2019-03-05       Impact factor: 5.923

7.  Clinical Significance of Circulating Tumor Cells (CTCs) and Survivin on Predicting Prognosis in Thyroid Cancer Patients.

Authors:  Xun Weng; Yujiao Cai
Journal:  Dis Markers       Date:  2022-01-31       Impact factor: 3.434

8.  Potential values of circulating tumor cell for detection of recurrence in patients of thyroid cancer: a diagnostic meta-analysis.

Authors:  Ming-Xing Liang; Yin-Jiao Fei; Kai Yang; Wen-Juan Tang; Xin-Hui Cao; Jin-Hai Tang
Journal:  BMC Cancer       Date:  2022-09-05       Impact factor: 4.638

9.  Circulating epithelial cell counts for monitoring the therapeutic outcome of patients with papillary thyroid carcinoma.

Authors:  Ching-Ping Tseng; Kong-Kit Leong; Miaw-Jene Liou; Hsueh-Ling Hsu; Hung-Chih Lin; Yi-An Chen; Jen-Der Lin
Journal:  Oncotarget       Date:  2017-08-24

Review 10.  Liquid Biopsy in Thyroid Cancer: New Insight.

Authors:  Fatemeh Khatami; Seyed Mohammad Tavangar
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2018-07-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.